右艾夫他濱

右艾夫他濱
	IUPAC名; 2′,3′-Didehydro-2′,3′-dideoxy-5-fluorocytidine
	系統名; 4-Amino-5-fluoro-1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-1-yl]pyrimidin-2(1H)-one
別名	Reverset
識別
CAS號	134379-77-4
PubChem	64973
ChemSpider	58498
SMILES	F\C1=C\N(C(=O)\N=C1\N)[C@@H]/2O[C@@H](\C=C\2)CO;
InChI	1/C9H10FN3O3/c10-6-3-13(9(15)12-8(6)11)7-2-1-5(4-14)16-7/h1-3,5,7,14H,4H2,(H2,11,12,15)/t5-,7+/m0/s1;
InChIKey	HSBKFSPNDWWPSL-CAHLUQPWBD
KEGG	D03981
性質
化學式	C9H10FN3O3
摩爾質量	227.19 g·mol−1
	若非註明，所有數據均出自標準狀態（25 ℃，100 kPa）下。

右艾夫他濱（INN：Dexelvucitabine）是一種用於治療人類免疫缺陷病毒感染的實驗藥物，不過已經研發失敗。它是一種胞苷核苷類似物和核苷逆轉錄酶抑制劑。^[1]，可在體外抑制HIV-1複製。在II期臨床試驗中，有一些跡象表明，感染人類免疫缺陷病毒的患者的平均病毒載量有所下降。^[2]^[3]

2006年4月3日，開發右艾夫他濱的製藥公司Pharmasset（英語：Pharmasset）和因賽特宣布決定停止該藥物的進一步試驗和開發，因為在II期臨床試驗中4級高脂酶血症（血液中脂肪酶過量）的發生率增加。^[1]^[4]

參考資料

^ ^1.0 ^1.1 PubChem. Dexelvucitabine. pubchem.ncbi.nlm.nih.gov. [2022-04-07] （英語）.
^ Hernandez-Santiago, Brenda I.; Mathew, Judy S.; Rapp, Kim L.; Grier, Jason P.; Schinazi, Raymond F. Antiviral and Cellular Metabolism Interactions between Dexelvucitabine and Lamivudine. Antimicrobial Agents and Chemotherapy. June 2007, 51 (6): 2130–2135. ISSN 0066-4804. PMC 1891415 . PMID 17403996. doi:10.1128/aac.01543-06.
^ Sobieszczyk, Magdalena E; Talley, Angela K; Wilkin, Timothy; Hammer, Scott M. Advances in antiretroviral therapy. Topics in HIV Medicine. 2005-03-01, 13 (1): 24–44 [2024-03-04]. ISSN 2161-5845. PMID 15849370. （原始內容存檔於2024-03-04）.
^ Ryder, Neil S. Discontinued drugs in 2006: anti-infectives. Expert Opinion on Investigational Drugs. 2007-12-01, 16 (12): 1867–1878. ISSN 1354-3784. PMID 18041997. S2CID 40129603. doi:10.1517/13543784.16.12.1867.

[:0-1] 1.0 ^1.1 PubChem. Dexelvucitabine. pubchem.ncbi.nlm.nih.gov. [2022-04-07] （英語）.

[2] Hernandez-Santiago, Brenda I.; Mathew, Judy S.; Rapp, Kim L.; Grier, Jason P.; Schinazi, Raymond F. Antiviral and Cellular Metabolism Interactions between Dexelvucitabine and Lamivudine. Antimicrobial Agents and Chemotherapy. June 2007, 51 (6): 2130–2135. ISSN 0066-4804. PMC 1891415 . PMID 17403996. doi:10.1128/aac.01543-06.

[3] Sobieszczyk, Magdalena E; Talley, Angela K; Wilkin, Timothy; Hammer, Scott M. Advances in antiretroviral therapy. Topics in HIV Medicine. 2005-03-01, 13 (1): 24–44 [2024-03-04]. ISSN 2161-5845. PMID 15849370. （原始內容存檔於2024-03-04）.

[4] Ryder, Neil S. Discontinued drugs in 2006: anti-infectives. Expert Opinion on Investigational Drugs. 2007-12-01, 16 (12): 1867–1878. ISSN 1354-3784. PMID 18041997. S2CID 40129603. doi:10.1517/13543784.16.12.1867.

[1]

[2]

[3]

[4]